Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy ...

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...

Please provide your email address to receive an email when new articles are posted on . Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% ...

The latest advances in asthma care combine revolutionary biologics, individualized immunotherapy, and targeted treatments that address specific triggers, ditching the “one-size-fits-all” approach. The ...

Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study ...

These can be classified in to those directed against cytokines involved in cell proliferation, survival and differentiation (i.e., IL-2, IL-4, IL-9 and IL-12), and those linked to the inflammatory ...

Medications that target inflammation, such as immunotherapy and steroids, treat allergic asthma, a common type of asthma. Identifying triggers and avoiding exposure to substances that exacerbate ...

Recent developments in allergen immunotherapy, improvements in primary care, and the emergence of a new treatment for other allergic conditions have improved the quality of care for seasonal allergies ...

ORLANDO (Nov. 6, 2025) – Two new studies being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shine a spotlight on oral immunotherapy ...

A simple blood test could make asthma treatment more precise, more effective—and potentially more affordable. Researchers from Karl Landsteiner University of Health Sciences (KL Krems) and the Medical ...

Will new phase III trial finally be the golden ticket with the FDA?